All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
ASPEN trial: Zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia
Bookmark this article
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. In this video, he discusses the phase III ASPEN trial, where treatment with the two Bruton's tyrosine kinase (BTK) inhibitors, zanubrutinib and ibrutinib, were compared in patients with Waldenström macroglobulinemia.
Constantine Tam, explains the mechanism of action of the two drugs, the patient response rates and safety results of the two treatment arms. He also explains that although the trial did not meet its primary endpoint (very good partial response), zanubrutinib showed greater tolerability and safety compared to ibrutinib.
ASPEN trial: zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
42 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox